Jump to content

Oncogene

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 208.22.79.1 (talk) at 20:11, 5 December 2012 (→Activation). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

For the journal, see Oncogene (journal).
Oncogene

An oncogene is a gene that has the potential to cause cancer.[1] In tumor cells, they are often mutated or expressed at high levels.[2]

Most normal cells undergo a programmed form of death (apoptosis). Activated oncogenes can cause those cells, that ought to die, to survive and proliferate instead.[3] Most oncogenes require an additional step, such as mutations in another gene, or environmental factors, such as viral infection, to cause cancer. Since the 1970s, dozens of oncogenes have been identified in human cancer. Many cancer drugs target the proteins encoded by oncogenes.[2][4][5][6]

Proto-oncogene

A proto-oncogene is a normal gene that can become an oncogene due to mutations or increased expression. The resultant protein may be termed an oncoprotein.[7] Proto-oncogenes code for proteins that help to regulate cell growth and differentiation. Proto-oncogenes are often involved in signal transduction and execution of mitogenic signals, usually through their protein products. Upon activation, a proto-oncogene (or its product) becomes a tumor-inducing agent, an oncogene.[8] Examples of proto-oncogenes include RAS, WNT, MYC, ERK, and TRK. The MYC gene is implicated in Burkitt's Lymphoma, which starts when a chromosomal translocation moves an enhancer sequence within the vicinity of the MYC gene. The MYC gene codes for widely used transcription factors. When the enhancer sequence is wrongly placed, these transcription factors are produced at much higher rates. Another example of an oncogene is the Bcr-Abl gene found on the Philadelphia Chromosome, a piece of genetic material seen in Chronic Myelogenous Leukemia caused by the translocation of pieces from chromosomes 9 and 22. Bcr-Abl codes for a receptor tyrosine kinase, which is constitutively active, leading to uncontrolled cell proliferation. (More information about the Philadelphia Chromosome below)

Activation

From proto-oncogene to oncogene

The proto-oncogene can become an oncogene by a relatively small modification of its original function. There are three basic activation types:

  • A mutation within a proto-oncogene, or within a regulatory region (for example the promoter region), can cause a change in the protein structure, causing
  • An increase in protein concentration, caused by
    • an increase of protein expression (through misregulation)
    • an increase of protein (mRNA) stability, prolonging its existence and thus its activity in the cell
    • gene duplication (one type of chromosome abnormality), resulting in an increased amount of protein in the cell
  • A chromosomal translocation (another type of chromosome abnormality), causing
    • There are 2 different types of chromosomal translocations that can occur:
  1. translocations events which relocate a proto-oncogene to a new chromosomal site that leads to higher expression
    • an increased gene expression in the wrong cell type or at wrong times
  2. translocations that lead to a fusion between a proto-oncogene and a 2nd gene (this creates a fusion protein with increased cancerous/oncogenic activity)
    • the expression of a constitutively active hybrid protein. This type of aberration in a dividing stem cell in the bone marrow leads to adult leukemia
    • An example of the 2nd possible translocation is known as the Philadelphia Chromosome. This chromosome was discovered in 1960 by Peter Nowell and David Hungerford, and it is a fusion of part of chromosome 22 and chromosome 9. The broken end of chromosome 22 contains the "BCR" gene, which fuses with a fragment of chromosome 9 that contains the "ABL1" gene. When these two chromosome fragments fuse the genes also fuse creating a new gene: "BRC-ABL" This fused gene encodes for a protein that displays high protein tyrosine kinase activity (this activity is due to the "ABL1" half of the protein).[9]


The expression of oncogenes can be regulated by microRNAs (miRNAs), small RNAs 21-25 nucleotides in length that control gene expression by downregulating them.[10] Mutations in such microRNAs (known as oncomirs) can lead to activation of oncogenes.[11] Antisense messenger RNAs could theoretically be used to block the effects of oncogenes.

Classification

There are several systems for classifying oncogenes,[12][13] but there is not yet a widely accepted standard. They are sometimes grouped both spatially (moving from outside the cell inwards) and chronologically (parallelling the "normal" process of signal transduction). There are several categories that are commonly used:

Category Examples Cancers Gene functions
Growth factors, or mitogens c-Sis glioblastomas, fibrosarcomas, osteosarcomas, breast carcinomas, and melanomas[14] induces cell proliferation.
Receptor tyrosine kinases epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), HER2/neu Breast cancer, gastrointestinal stromal tumours, non-small-cell lung cancer and pancreatic cancer[15] transduce signals for cell growth and differentiation.
Cytoplasmic tyrosine kinases Src-family, Syk-ZAP-70 family, and BTK family of tyrosine kinases, the Abl gene in CML - Philadelphia chromosome colorectal and breast cancers, melanomas, ovarian cancers, gastric cancers, head and neck cancers, pancreatice cancer, lung cancer, brain cancers, and blood cancers[16] mediate the responses to, and the activation receptors of cell proliferation, migration, differentiation, and survival [17]
Cytoplasmic Serine/threonine kinases and their regulatory subunits Raf kinase, and cyclin-dependent kinases (through overexpression). malignant melanoma, papillary thyroid cancer, colorectal cancer, and ovarian cancer[18] Involved in organism development, cell cycle regulation, cell proliferation, differentiation, cells survival, and apoptosis [19]
Regulatory GTPases Ras protein adenocarcinomas of the pancreas and colon, thyroid tumors, and myeloid leukemia[20] involved in signalling a major pathway leading to cell proliferation. [21]
Transcription factors myc gene malignant T-cell lymphomas and acute myleoid leukemias[22] breast cancer, pancreatic cancer, retinoblastoma, and small cell lung cancer -They regulate transcription of genes that induce cell proliferation.

More detailed information for the above Table:

  • Growth factors are usually secreted by specialized cells to induce cell proliferation in themselves, nearby cells, or distant cells. An oncogene may cause a cell to secrete growth factors even though it does not normally do so. It will thereby induce its own uncontrolled proliferation (autocrine loop), and proliferation of neighboring cells. It may also cause production of growth hormones in other parts of the body.
  • Receptor Tyrosine Kinases add phosphate groups to other proteins to turn them on or off. Receptor kinases add phosphate groups to receptor proteins at the surface of the cell (which receive protein signals from outside the cell and transmit them to the inside of the cell). Tyrosine kinases add phosphate groups to the amino acid tyrosine in the target protein. They can cause cancer by turning the receptor permanently on (constitutively), even without signals from outside the cell.
  • Ras is a small GTPase that hydrolyses GTP into GDP and phosphate. Ras is activated by growth factor signaling (i.e., EGF, TGFbeta) and acting like a binary switch (on/off) in growth signaling pathways. Downstream effectors of Ras include Raf, MEK, MEKK, MAPK, ERK, most of which in turn regulate genes that mediate cell proliferation.

Conversion of proto-oncogenes

Possible Pathways that turn Proto-oncogenes into Oncogenes

There are two mechanisms by which proto-oncogenes can be converted to cellular oncogenes:

Quantitative: Tumor formation is induced by an increase in the absolute number of proto-oncogene products or by its production in inappropriate cell types.

Qualitative: Conversion from proto-oncogene to transforming gene (c-onc) with changes in the nucleotide sequence that are responsible for the acquisition of the new properties.[23]


History

The term "oncogene" was coined in 1969 by National Cancer Institute scientists, Robert Huebner and George Todaro[24]

The first confirmed oncogene was discovered in 1970 and was termed src (pronounced sarc as in sarcoma). Src was in fact first discovered as an oncogene in a chicken retrovirus. Experiments performed by Dr G. Steve Martin of the University of California, Berkeley demonstrated that the Src was indeed the oncogene of the virus. The first nucleotide sequence of v-src was sequenced 1980 by A.P. Czernilofsky et al. [25]

In 1976 Drs. Dominique Stehelin, J. Michael Bishop and Harold E. Varmus of the University of California, San Francisco demonstrated that oncogenes were activated proto-oncogenes, found in many organisms including humans. For this discovery Bishop and Varmus were awarded the Nobel Prize in Physiology or Medicine in 1989.[26]

See also

References

  1. ^ Wilbur, Beth, editor. The World of the Cell, Becker, W.M., et al., 7th ed. San Francisco, CA; 2009.
  2. ^ a b Kimball's Biology Pages. "Oncogenes" Free full text
  3. ^ The Nobel Prize in Physiology or Medicine 2002. Illustrated presentation.
  4. ^ Croce CM (2008). "Oncogenes and cancer". N Engl J Med. 358 (5): 502–11. doi:10.1056/NEJMra072367. PMID 18234754. {{cite journal}}: Unknown parameter |month= ignored (help)
  5. ^ Yokota J (2000). "Tumor progression and metastasis". Carcinogenesis. 21 (3): 497–503. doi:10.1093/carcin/21.3.497. PMID 10688870. {{cite journal}}: Unknown parameter |month= ignored (help)
  6. ^ The Nobel Prize in Physiology or Medicine 1989 to J. Michael Bishop and Harold E. Varmus for their discovery of "the cellular origin of retroviral oncogenes".
  7. ^ Chapter 20 - NEOPLASMS OF THE THYROID - in: Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson. Robbins Basic Pathology. Philadelphia: Saunders. ISBN 1-4160-2973-7.{{cite book}}: CS1 maint: multiple names: authors list (link) 8th edition.
  8. ^ Todd R, Wong DT (1999). "Oncogenes". Anticancer Res. 19 (6A): 4729–46. PMID 10697588.
  9. ^ Chial, H (2008). "Proto-oncogenes to Oncogenes to Cancer". Nature Education. 1 (1).
  10. ^ Negrini M, Ferracin M, Sabbioni S, Croce CM (2007). "MicroRNAs in human cancer: from research to therapy". J Cell Sci. 120 (Pt 11): 1833–40. doi:10.1242/jcs.03450. PMID 17515481. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  11. ^ Esquela-Kerscher A, Slack FJ (2006). "Oncomirs - microRNAs with a role in cancer". Nat Rev Cancer. 6 (4): 259–69. doi:10.1038/nrc1840. PMID 16557279. {{cite journal}}: Unknown parameter |month= ignored (help)
  12. ^ THE Medical Biochemistry Page
  13. ^ Classification of Oncogene Function
  14. ^ Press, Richard (June 1, 1989). "Control of the Expression of c-sis mRNA in Human Glioblastoma Cells by Phorbol Ester and Transforming Growth Factor ß1". Cancer Research (49): 2914–2920. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  15. ^ Gschwind, Andreas (May 2004). "Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy". Nature Reviews Cancer. 4 (5): 361–370. doi:10.1038/nrc1360. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  16. ^ Summy, Justin M. (1 January 2003). "Src family kinases in tumor progression and metastasis". Cancer and Metastasis Reviews. 22 (4): 337–358. doi:10.1023/A:1023772912750.
  17. ^ Thomas, Sheila M. (1 November 1997). "CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES". Annual Review of Cell and Developmental Biology. 13 (1): 513–609. doi:10.1146/annurev.cellbio.13.1.513. {{cite journal}}: |access-date= requires |url= (help); Check date values in: |accessdate= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  18. ^ Garnett, Mathew J. (1 October 2004). "Guilty as charged: B-RAF is a human oncogene". Cancer Cell. 6 (4): 313–319. doi:10.1016/j.ccr.2004.09.022. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  19. ^ Leicht, D (August 2007). "Rafkinases: Function, regulation and role in human cancer". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1773 (8): 1196–1212. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  20. ^ Bos, JL (1989 Sep 1). "ras oncogenes in human cancer: a review". Cancer research. 49 (17): 4682–9. PMID 2547513. {{cite journal}}: Check date values in: |date= (help)
  21. ^ Hilgenfeld, Rolf (1 December 1995). "Regulatory GTPases". Current Opinion in Structural Biology. 5 (6): 810–817. doi:10.1016/0959-440X(95)80015-8.
  22. ^ Felsher, Dean W. (August 1999). "Reversible Tumorigenesis by MYC in Hematopoietic Lineages". Molecular Cell. 4 (2): 199–207. doi:10.1016/S1097-2765(00)80367-6. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  23. ^ Emery, Alan E. H.; Mueller, Robert Francis; Young, Ian T.; Ian D., MD Young (2001). "Oncogene". Emery's elements of medical genetics. Edinburgh: Churchill Livingstone. ISBN 0-443-07125-X.{{cite book}}: CS1 maint: multiple names: authors list (link)
  24. ^ The Emperor of All Maladies, Siddhartha Mukherjee, 2011, p. 363, endnote.
  25. ^ (A.P. Czernilofsky et al., 1980, Nature Vol 287, pp 198-203).
  26. ^ Nobel Prize in Physiology or Medicine for 1989 jointly to J. Michael Bishop and Harold E. Varmus for their discovery of "the cellular origin of retroviral oncogenes". Press Release.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Oncogene&oldid=526585186"